Dr Rovel Colaco

Consultant Clinical Oncologist

BSc Hons, MB CHB, MRCP, FRCR

Year qualified:2001

Specialty

Personal profile

Dr Colaco is a consultant clinical oncologist with a specialist interest in proton therapy, stereotactic radiotherapy and adult primary brain tumours. He also specialises in stereotactic radiotherapy for brain metastases and oligo-metastatic cancers such as metastatic breast and lung cancers.

After completing his training as a specialist registrar in Clinical Oncology at the Christie, Dr Colaco was selected as the first UK doctor to train in proton therapy spending 12 months working in proton therapy at the University of Florida Proton Therapy Institute in Jacksonville, Florida.

He was subsequently the first graduate of the Stereotactic Radiosurgery and Radiotherapy program at Yale University in Connecticut, USA, where he worked with a variety of radiotherapy delivery platforms including the Cyberknife, Gammaknife and Novalis TX treating patients with stereotactic radiosurgery(SRS) for brain metastases and stereotactic ablative radiotherapy (SABR) for both primary lung tumours and oligo-metastatic disease from other primary cancer sites.

Following his return from the United States, he was appointed as a consultant clinical oncologist at The Christie in 2014.

Professional Memberships

  • Fellow of the Royal College of Radiologists
  • Children’s Cancer and Leukaemia Group

Clinical Interests

Dr Colaco specialises in the treatment of primary adult brain tumours and paediatric tumours along with stereotactic radiotherapy for brain metastases and high dose radiotherapy for cancers with limited metastases/oligometastases.

He also sees patients for proton therapy and is involved in the development of The Christie proton beam centre and in the Christie program for oligo-metastatic disease including treating tumours which have metastasised to bone, spine and lymph nodes with SABR.

He is the principal investigator at the Christie for the CORE trial treating patients with oligo-metastatic breast, lung and prostate cancers with stereotactic radiotherapy.

He has published several peer reviewed manuscripts on stereotactic radiotherapy and proton therapy.

Want to look at other consultants?